A Phase 1 Study to Evaluate the Safety and Clinical Activity of Intravesicular CAVATAK (Coxsackievirus A21, CVA21) Alone and in Sequential Combination With Low Dose Mitomycin C in Patients With Non-Muscle Invasive Bladder Cancer

Trial Profile

A Phase 1 Study to Evaluate the Safety and Clinical Activity of Intravesicular CAVATAK (Coxsackievirus A21, CVA21) Alone and in Sequential Combination With Low Dose Mitomycin C in Patients With Non-Muscle Invasive Bladder Cancer

Completed
Phase of Trial: Phase I/II

Latest Information Update: 12 May 2017

At a glance

  • Drugs CVA 21 (Primary) ; Mitomycin
  • Indications Bladder cancer
  • Focus Adverse reactions
  • Acronyms CANON
  • Sponsors Viralytics
  • Most Recent Events

    • 11 Oct 2016 Results assessing tumor response presented at the 41st European Society for Medical Oncology Congress (2016).
    • 31 Jul 2016 Status changed from active, no longer recruiting to completed.
    • 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top